These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24646608)

  • 1. Study claiming Tamiflu saved lives was based on "flawed" analysis.
    Kmietowicz Z
    BMJ; 2014 Mar; 348():g2228. PubMed ID: 24646608
    [No Abstract]   [Full Text] [Related]  

  • 2. Principal author of PRIDE study responds to news story in The BMJ claiming that the study was based on "flawed" analysis.
    Nguyen-Van-Tam JS
    BMJ; 2014 Apr; 348():g2935. PubMed ID: 24780605
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of neuraminidase inhibitors for severe influenza.
    Fry AM
    Lancet Respir Med; 2014 May; 2(5):346-8. PubMed ID: 24815800
    [No Abstract]   [Full Text] [Related]  

  • 4. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Wolkewitz M; Schumacher M
    Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
    [No Abstract]   [Full Text] [Related]  

  • 5. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
    Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
    [No Abstract]   [Full Text] [Related]  

  • 6. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Jones M; Del Mar C; Hama R
    Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
    [No Abstract]   [Full Text] [Related]  

  • 7. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Antes G; Meerpohl JJ
    Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
    [No Abstract]   [Full Text] [Related]  

  • 8. Editor in chief's reply to Nguyen-Van-Tam.
    Godlee F
    BMJ; 2014 Apr; 348():g2951. PubMed ID: 24780322
    [No Abstract]   [Full Text] [Related]  

  • 9. Authors' reply to Mark Jones's critique of the study by Muthuri and colleagues reported in The BMJ.
    Myles PR; Leonardi-Bee J;
    BMJ; 2014 Apr; 348():g2990. PubMed ID: 24788485
    [No Abstract]   [Full Text] [Related]  

  • 10. Authors' reply to Mark Jones's second critique of the study by Muthuri and colleagues reported in The BMJ.
    Myles PR; Leonardi-Bee J;
    BMJ; 2014 Apr; 348():g3004. PubMed ID: 24788389
    [No Abstract]   [Full Text] [Related]  

  • 11. Mark Jones's reply to Myles and Leonardi-Bee's response to his critique of their paper reported in The BMJ.
    Jones M
    BMJ; 2014 Apr; 348():g3001. PubMed ID: 24788584
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
    Magano J
    Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
    [No Abstract]   [Full Text] [Related]  

  • 14. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
    Weber JT; Nicoll A; Bridges CB; Ciancio BC
    BMJ; 2010 Jan; 340():c130. PubMed ID: 20071425
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations.
    Millard PS
    Ann Intern Med; 2014 Oct; 161(8):JC2. PubMed ID: 25329219
    [No Abstract]   [Full Text] [Related]  

  • 17. Should neuraminidase inhibitors be prescribed for patients with influenza?
    Patel DM; Pitts SR; Hargraves J
    Ann Emerg Med; 2014 Jan; 63(1):54-5. PubMed ID: 23932720
    [No Abstract]   [Full Text] [Related]  

  • 18. Oseltamivir and zanamivir have limited effect on symptoms and do not reduce hospitalisation or serious complications of influenza.
    Ebell MH
    Evid Based Med; 2014 Dec; 19(6):211. PubMed ID: 24985901
    [No Abstract]   [Full Text] [Related]  

  • 19. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.
    Miller PE; Rambachan A; Hubbard RJ; Li J; Meyer AE; Stephens P; Mounts AW; Rolfes MA; Penn CR
    PLoS One; 2012; 7(9):e43491. PubMed ID: 22984431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
    Toniolo Neto J
    Sao Paulo Med J; 2014; 132(4):256-7. PubMed ID: 25055075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.